Ben Beerle

Cooley advised Accel, a long-standing investor of Squarespace, in connection with Squarespace’s definitive agreement to go private by Permira in an approximately $6.9 billion all-cash transaction.

Cooley advised RayzeBio, a clinical-stage radiopharmaceutical therapeutics (RPT) company with an innovation-leading position in actinium-based RPTs and a pipeline of potentially first-in-class and best-in-class drug development programs, on its definitive agreement to be acquired by Bristol Myers Squibb.

Cooley advised Carmot Therapeutics, a clinical-stage biotechnology company dedicated to developing life-changing therapeutics for people living with metabolic diseases including obesity and diabetes, on its definitive merger agreement in which Roche will acquire Carmot.

Cooley advised Apollo Endosurgery, a medical device company, on its agreement to be acquired by Boston Scientific in an all-cash transaction with an enterprise value of approximately $615 million.

Cooley advised Tmunity Therapeutics, a clinical-stage biotechnology company, on its agreement to sell to Kite, a global biopharmaceutical company. Partners Mark Weeks, Ben Beerle and Marya Postner led the Cooley team.